LENZ
Income statement / Annual
Last year (2025), LENZ Therapeutics Inc.'s total revenue was $19.09 M,
and the percentage change from the previous year is not available.
In 2025, LENZ Therapeutics Inc.'s net income was -$82.13 M.
See LENZ Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$19.09 M |
$0.00 |
$0.00 |
$15.00 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$705.00 K
|
$58.00 K
|
$0.00
|
$0.00
|
$734.00 K
|
$121.00 K
|
$0.00
|
| Gross Profit |
$18.38 M
|
-$58.00 K
|
$0.00
|
$15.00 M
|
-$734.00 K
|
-$121.00 K
|
$0.00
|
| Gross Profit Ratio |
0.96
|
0
|
0
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$18.67 M
|
$29.80 M
|
$59.50 M
|
$21.13 M
|
$37.93 M
|
$9.12 M
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$90.85 M
|
$28.75 M
|
$12.93 M
|
$4.36 M
|
$21.78 M
|
$4.26 M
|
$29.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$109.52 M
|
$58.55 M
|
$72.43 M
|
$25.48 M
|
$59.71 M
|
$13.38 M
|
$29.00 K
|
| Cost And Expenses |
$110.23 M
|
$58.61 M
|
$72.43 M
|
$25.48 M
|
$60.44 M
|
$13.50 M
|
$29.00 K
|
| Interest Income |
$9.76 M
|
$8.55 M
|
$2.19 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$40.00 K
|
$80.00 K
|
| Depreciation & Amortization |
$287.00 K
|
$58.00 K
|
$15.00 K
|
$8.00 K
|
$734.00 K
|
$121.00 K
|
$171.86 K
|
| EBITDA |
-$81.34 M |
-$49.71 M |
-$70.13 M |
-$10.46 M |
-$70.03 M |
-$68.21 M |
$142.86 K |
| EBITDA Ratio |
-4.26
|
0
|
0
|
-0.7
|
0
|
0
|
0
|
| Operating Income Ratio |
-4.77
|
0
|
0
|
-0.7
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$9.51 M
|
$8.84 M
|
$2.28 M
|
$19.00 K
|
-$10.32 M
|
-$54.87 M
|
-$80.00 K
|
| Income Before Tax |
-$81.63 M
|
-$49.77 M
|
-$70.15 M
|
-$10.46 M
|
-$70.76 M
|
-$68.37 M
|
-$109.00 K
|
| Income Before Tax Ratio |
-4.28
|
0
|
0
|
-0.7
|
0
|
0
|
0
|
| Income Tax Expense |
$502.00 K
|
$1.00 K
|
-$179.00 K
|
$347.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$82.13 M
|
-$49.77 M
|
-$69.97 M
|
-$10.81 M
|
-$70.76 M
|
-$68.37 M
|
-$109.00 K
|
| Net Income Ratio |
-4.3
|
0
|
0
|
-0.72
|
0
|
0
|
0
|
| EPS |
-2.85 |
-2.34 |
-15.3 |
-12.8908 |
-8.5384 |
-8.24 |
-0.0131 |
| EPS Diluted |
-2.85 |
-2.34 |
-15.3 |
-12.8908 |
-8.5384 |
-8.24 |
-0.0131 |
| Weighted Average Shares Out |
$28.81 M
|
$21.28 M
|
$8.15 M
|
$7.84 M
|
$8.29 M
|
$8.30 M
|
$8.30 M
|
| Weighted Average Shares Out Diluted |
$28.81 M
|
$21.28 M
|
$8.15 M
|
$7.84 M
|
$8.29 M
|
$8.30 M
|
$8.30 M
|
| Link |
|
|
|
|
|
|
|
